Overview

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

Status:
Completed
Trial end date:
2017-10-09
Target enrollment:
Participant gender:
Summary
The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
BI 409306